Objective The aims of this study were to explore the effect of Profilin-1 on vascular injury caused by advanced glycation end products, So as to provide a new therapeutic approach with diabetic vascular complications.
Methods Human umbilical vein endothelial cells were incubated with different concentrations of AGEs-BSA (50 mg·L−1, 100 mg·L−1, 200 mg·L−1) for various periods of time (6–24 h). The levels of ADMA and NO in the conditioned medium, the protein expression of Profilin-1 for cells were determined.
Results AGEs-BSA increased the protein expression of Profilin-1 and ADMA in a concentration and time-dependent manner. Incubation with high concentration glucose (30 mmol/l) for 24 h elevated the levels of NO, and AGEs-BSA (200 mg·L−1) decrease the levels of NO. AGEs-BSA (200 mg·L−1) could decrease the levels of NO in the conditioned medium, the difference were significant after 24 h.
Conclusion Profilin-1 may be involved in “metabolic memory” induced by the advanced glycation end products.
- Advanced glycation end products
- asymmetric dimethylarginine
- Nitric oxide
- cardiovascular disease